The Global Pharmaceutical Company AstraZeneca has donated prostate biopsy equipment to the Ministry of Health in Ghana.
The donation of reusable prostate biopsy guns and disposable prostate biopsy needles will support the Ministry of Health’s ongoing efforts to improve the overall prostate diagnosis, experience and results for patients.
The World Health Organisation reports that 2129 new cases of prostate cancer were reported in Ghana in 2020, with prostate cancer the second most frequent cancer in men, excluding non-melanoma skin cancers.
This figure highlights the importance and urgency of ensuring that those at risk of prostate cancer have timely access to healthcare services, such as
appropriate diagnosis. Early diagnosis of prostate cancer could lead to benefits in survival if it involves the diagnosis at an earlier, more treatable stage, and that treatment options for the
disease exist.
The Country lead for AstraZeneca ,Mawuli Atiemo in an interview said ,there is no doubt that urgent progress on cancer is sorely needed and prostate cancer remains the most common form of cancer in men worldwide, despite an increase in the number of available therapies.
He said AstraZeneca is looking at ways to keep driving forward progress in cancer care and are dedicated to helping improve the outcomes of men affected by prostate cancer and the donation is part of this
commitment.
The Chief Programme officer of Medical & Dental, Ministry of Health (MOH),Dr.Baffour Awuah representing the Chief Director , said they are grateful to AstraZeneca for this kind gesture to support the Ministry,Non-Communicable Diseases (NCD) policies, which includes cancer and the donation will go a long way to support the NCD policy, specifically the objective of early
diagnosis.
AstraZeneca are looking at ways to keep driving forward progress in cancer care and are dedicated to helping improve the outcomes of men affected by prostate cancer.
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-ledbiopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, Respiratory, Vaccines & Immunology and Rare Diseases.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
